| [1] |
Bukavina L, Bensalah K, Bray F, et al. Epidemiology of renal cell carcinoma: 2022 update[J]. Eur Urol, 2022, 82(5): 529-542. DOI: 10.1016/j.eururo.2022.08.019.
|
| [2] |
Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma[J]. N Engl J Med, 2024, 390(15): 1359-1371. DOI: 10.1056/NEJMoa2312695.
|
| [3] |
Tabbara MM, González J, Martucci M, et al. Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus[J]. Biomedicines, 2023, 11(1): 204. DOI: 10.3390/biomedicines11010204.
|
| [4] |
Stewart GD, Welsh SJ, Ursprung S, et al. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)[J]. Br J Cancer, 2022, 127(6): 1051-1060. DOI: 10.1038/s41416-022-01883-7.
|
| [5] |
Bex A, Abu-Ghanem Y, Van Thienen JV, et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx)[J]. J Clin Oncol, 2022, 40(6_suppl): 289. DOI: 10.1200/jco.2022.40.6_suppl.289.
|
| [6] |
Rini BI, Plimack ER, Takagi T, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma[J]. J Urol, 2015, 194(2): 297-303. DOI: 10.1016/j.juro.2015.03.096.
|
| [7] |
Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery[J]. J Urol, 2012, 187(5): 1548-1554. DOI: 10.1016/j.juro.2011.12.075.
|
| [8] |
Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma[J]. Eur Urol, 2014, 66(5): 874-880. DOI: 10.1016/j.eururo.2014.01.035.
|
| [9] |
Gorin MA, Patel HD, Rowe SP, et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma[J]. Eur Urol Oncol, 2022, 5(1): 113-117. DOI: 10.1016/j.euo.2021.04.002.
|
| [10] |
Carlo MI, Attalla K, Mazaheri Y, et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy[J]. Eur Urol, 2022, 81(6): 570-573. DOI: 10.1016/j.eururo.2022.01.043.
|
| [11] |
Karam JA, Msaouel P, Haymaker CL, et al. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma[J]. Nat Commun, 2023, 14(1): 2684. DOI: 10.1038/s41467-023-38342-7.
|
| [12] |
Huang J, Wang Y, Xu F, et al. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial[J]. J Immunother Cancer, 2024, 12(6): e008475. DOI: 10.1136/jitc-2023-008475.
|
| [13] |
Gu L, Peng C, Liang Q, et al. Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena Cava tumor thrombus: NEOTAX, a phase 2 study[J]. Signal Transduct Target Ther, 2024, 9(1): 264. DOI: 10.1038/s41392-024-01990-2.
|
| [14] |
Zhang S, Ji C, Liu G, et al. A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC)[J]. J Clin Oncol, 2024, 42(4_suppl): 420. DOI: 10.1200/jco.2024.42.4_suppl.420.
|
| [15] |
Bindayi A, Hamilton ZA, McDonald ML, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma[J]. Urol Oncol Semin Orig Investig, 2018, 36(1): 31-37. DOI: 10.1016/j.urolonc.2017.07.015.
|
| [16] |
Motzer RJ, Russo P, Haas N, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial[J]. Eur Urol, 2021, 79(3): 334-338. DOI: 10.1016/j.eururo.2020.12.029.
|
| [17] |
Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results[J]. Eur Urol, 2018, 73(1): 62-68. DOI: 10.1016/j.eururo.2017.09.008.
|
| [18] |
Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial[J]. Ann Oncol, 2018, 29(12): 2371-2378. DOI: 10.1093/annonc/mdy454.
|
| [19] |
Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy[J]. N Engl J Med, 2016, 375(23): 2246-2254. DOI: 10.1056/NEJMoa1611406.
|
| [20] |
Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial[J]. Lancet, 2016, 387(10032): 2008-2016. DOI: 10.1016/S0140-6736(16)00559-6.
|
| [21] |
Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2022, 400(10358): 1103-1116. DOI: 10.1016/S0140-6736(22)01658-0.
|
| [22] |
Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial[J]. Lancet, 2023, 401(10379): 821-832. DOI: 10.1016/S0140-6736(22)02574-0.
|
| [23] |
Allaf ME, Kim SE, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2024, 25(8): 1038-1052. DOI: 10.1016/S1470-2045(24)00211-0.
|
| [24] |
Bedke J, Ghanem YA, Albiges L, et al. Updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma[J]. Eur Urol, 2025, 87(4): 491-496. DOI: 10.1016/j.eururo.2025.01.014.
|